David M. Milgraum

2 months ago | onlinelibrary.wiley.com | Divya Shan |Marisa Riley |David M. Milgraum

1 Introduction Dupilumab, a monoclonal antibody targeting the interleukin-4 receptor alpha, has transformed the management of moderate-to-severe atopic dermatitis. While it offers substantial relief for many patients, emerging reports have identified an adverse effect not highlighted in initial clinical trials: erythematous eruptions on the head and neck [1].